EVALUATION OF THERAPEUTIC AND BIOCHEMICAL EFFECTS OF VERAPAMIL IN SCHIZOPHRENIA

维拉帕米治疗精神分裂症的治疗和生化效果评价

• 批准号: 4691976
• 负责人: P K NARANG
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/4691976
• 关键词: calcium channel blockers; calcium disorder; cerebrospinal fluid; drug metabolism; high performance liquid chromatography; human subject; mental disorder chemotherapy; psychopharmacology; schizophrenia; tissue /cell culture; verapamil

Abnormalities in Ca++ in the CSF have been observed in manic, depressed and schizophrenic patients. The present study explores the role of Ca++ channel blockers in schizophrenia. By employing a new sensitive method for the quantitation of verapamil and its two active metabolites, we have demonstrated for the first time the partitioning of verapamil and its metabolite into the CSF. By estimating the free fraction of the drug in plasma and employing correlation analysis for drug levels in CSF and plasma, we have found the drug transfer process across the ependymal surface to be diffusion controlled. In vitro binding, studies can approximate partitioning of verapamil into the CNS, and hence can provide a measure of correlating clinical outcome or other biochemical measures presently being investigated.

躁狂、抑郁和抑郁患者脑脊液中钙离子含量异常。 精神分裂症患者。本研究探讨了钙离子的作用。 精神分裂症的通道阻滞剂。通过采用一种新的敏感方法 维拉帕米及其两种活性代谢物的定量 首次证明了维拉帕米及其药物的分配 代谢产物进入脑脊液。通过估算药物在体内的游离度 血药浓度与脑脊液药物浓度的相关性分析 血浆，我们发现了跨室管膜的药物转移过程 要扩散控制的表面。在体外结合方面，研究可以 维拉帕米在中枢神经系统中的近似分区，因此可以提供 与临床结果或其他生化指标相关的指标 目前正在接受调查。